{"id":"inotuzumab-ozogamicin-dose-level-1","safety":{"commonSideEffects":[{"rate":"70–80","effect":"Thrombocytopenia"},{"rate":"60–75","effect":"Neutropenia"},{"rate":"50–65","effect":"Anemia"},{"rate":"40–50","effect":"Infection"},{"rate":"30–40","effect":"Nausea"},{"rate":"20–30","effect":"Vomiting"},{"rate":"10–20","effect":"Hepatotoxicity"},{"rate":"5–15","effect":"Sinusoidal obstruction syndrome (SOS)"}]},"_chembl":{"chemblId":"CHEMBL2108611","moleculeType":"Antibody drug conjugate"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug targets CD22, a surface antigen expressed on B-lineage hematologic malignancies. Upon binding, the antibody-drug conjugate is internalized and releases calicheamicin, a potent DNA-damaging agent, inside the tumor cell. This targeted delivery mechanism concentrates cytotoxicity on malignant B cells while sparing normal tissues.","oneSentence":"Inotuzumab ozogamicin is an anti-CD22 monoclonal antibody conjugated to a cytotoxic calicheamicin payload that binds to CD22 on B-cell lymphomas and delivers cell-killing chemotherapy directly to tumor cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:06.067Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)"},{"name":"Relapsed or refractory B-cell non-Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT04307576","phase":"PHASE3","title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"Mats Heyman","startDate":"2020-07-13","conditions":"Leukemia, Acute Lymphoblastic","enrollment":6430},{"nctId":"NCT06985485","phase":"PHASE2","title":"Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-05-17","conditions":"Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab","enrollment":26},{"nctId":"NCT05748171","phase":"PHASE2","title":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-05-17","conditions":"ACUTE LYMPHOBLASTIC LEUKEMIA","enrollment":100},{"nctId":"NCT01679119","phase":"PHASE2","title":"Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy","status":"COMPLETED","sponsor":"University College, London","startDate":"2013-10","conditions":"Diffuse Large B Cell Lymphoma","enrollment":129},{"nctId":"NCT06863259","phase":"PHASE1","title":"Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2025-05-21","conditions":"B-cell Acute Lymphoblastic Leukemia","enrollment":28},{"nctId":"NCT06287229","phase":"PHASE1, PHASE2","title":"Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-07-11","conditions":"Relapsed/Refractory, B-cell Acute Lymphocytic Leukemia","enrollment":40},{"nctId":"NCT03913559","phase":"PHASE2","title":"Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-05-14","conditions":"Acute Lymphoblastic Leukemia","enrollment":5},{"nctId":"NCT05016947","phase":"PHASE1","title":"Venetoclax Plus Inotuzumab for B-ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-09-24","conditions":"B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, ALL","enrollment":23},{"nctId":"NCT05456698","phase":"PHASE2","title":"Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-10-18","conditions":"Acute Lymphocytic Leukemia","enrollment":31},{"nctId":"NCT06387121","phase":"PHASE2","title":"Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-04-02","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":53},{"nctId":"NCT03104491","phase":"PHASE1, PHASE2","title":"Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Leland Metheny","startDate":"2017-07-31","conditions":"Acute Lymphocytic Leukemia","enrollment":44},{"nctId":"NCT05303792","phase":"PHASE2","title":"Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-06-09","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma","enrollment":68},{"nctId":"NCT06861348","phase":"PHASE2","title":"Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-03-01","conditions":"Leukemia, Lymphocytic, Acute","enrollment":23},{"nctId":"NCT06427330","phase":"PHASE2","title":"Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-07-02","conditions":"Acute Lymphoid Leukemia","enrollment":21},{"nctId":"NCT01134575","phase":"PHASE2","title":"CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-06-04","conditions":"Acute Lymphoblastic Leukemia","enrollment":90},{"nctId":"NCT03677596","phase":"PHASE4","title":"A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-07-01","conditions":"Leukemia, Precursor b-Cell Lymphoblastic Leukemia-Lymphoma, ACUTE LYMPHOBLASTIC LEUKEMIA","enrollment":102},{"nctId":"NCT03962465","phase":"PHASE1","title":"Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Virginia","startDate":"2022-07-22","conditions":"B-cell Acute Lymphoblastic Leukemia","enrollment":36},{"nctId":"NCT02311998","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-04-16","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells","enrollment":22},{"nctId":"NCT03991884","phase":"PHASE1","title":"Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2019-09-24","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia","enrollment":24},{"nctId":"NCT01925131","phase":"PHASE1","title":"S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2014-06-13","conditions":"Acute Leukemias of Ambiguous Lineage, B-cell Adult Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT03460522","phase":"PHASE2","title":"Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL","status":"UNKNOWN","sponsor":"Nicola Goekbuget","startDate":"2018-05-02","conditions":"Precursor Cell Lymphoblastic Leukemia","enrollment":65},{"nctId":"NCT03094611","phase":"PHASE2","title":"Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-11-30","conditions":"CD22 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia","enrollment":4},{"nctId":"NCT01055496","phase":"PHASE1","title":"Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-03","conditions":"Lymphoma, B-Cell","enrollment":103},{"nctId":"NCT01564784","phase":"PHASE3","title":"A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-08-02","conditions":"Acute Lymphoblastic Leukemia","enrollment":326},{"nctId":"NCT01232556","phase":"PHASE3","title":"A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy","status":"TERMINATED","sponsor":"Pfizer","startDate":"2011-04-04","conditions":"Lymphoma, Non-Hodgkin","enrollment":338},{"nctId":"NCT00073749","phase":"PHASE1","title":"Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-08","conditions":"Lymphoma, B-Cell","enrollment":79},{"nctId":"NCT00562965","phase":"PHASE3","title":"Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)","status":"TERMINATED","sponsor":"Pfizer","startDate":"2007-11","conditions":"Lymphoma, Follicular","enrollment":29},{"nctId":"NCT01363297","phase":"PHASE2","title":"Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-08","conditions":"Acute Lymphocytic Leukemia","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Besponsa"],"phase":"marketed","status":"active","brandName":"Inotuzumab ozogamicin-dose level 1","genericName":"Inotuzumab ozogamicin-dose level 1","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inotuzumab ozogamicin is an anti-CD22 monoclonal antibody conjugated to a cytotoxic calicheamicin payload that binds to CD22 on B-cell lymphomas and delivers cell-killing chemotherapy directly to tumor cells. Used for Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), Relapsed or refractory B-cell non-Hodgkin lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}